Meta-analysis of Rho kinase inhibitor Ripasudil in the treatment of glaucoma
Author:
Corresponding Author:

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To evaluate the efficacy and safety of ripasudil in the treatment of glaucoma in recent years by Meta-analysis.

    METHODS:According to the Cochrane systematic review method, we searched three databases(Pubmed, Web of Knowledge and CNKI). The change of intraocular pressure was used to assess the effect of ripasudil, WMD with 95% confidence intervals(CI)were used to report the outcome. Subgroup analysis was performed according to different types of glaucoma.

    RESULTS:A total of 9 trials all in English, totally 3446 patients, Meta-analysis showed that compared with before-treated groups, after-treated groups have significant lower IOP(Test of WMD= -2.96 95% CI: -3.48 to -2.45, P<0.001), which indicates that ripasudil has great efficacy of curing glaucoma.

    CONCLUSION:Ripasudil have significant efficacy in reducing IOP, which can be used as a treatment for glaucoma.

    Reference
    Related
    Cited by
Get Citation

Lan Ma, Ruo-Lan Qian. Meta-analysis of Rho kinase inhibitor Ripasudil in the treatment of glaucoma. Guoji Yanke Zazhi( Int Eye Sci) 2019;19(10):1717-1721

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:May 15,2019
  • Revised:September 11,2019
  • Adopted:
  • Online: September 20,2019
  • Published: